Quince Therapeutics, Inc. (QNCX) — 8-K Filings

8-K Filings (13)

• Quince Therapeutics Amends Articles of Incorporation — Apr 9, 2026 Risk: low
  On April 9, 2026, Quince Therapeutics, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation. These amendments, filed under Item 5.03,
• 8-K Filing — Mar 30, 2026
• Quince Therapeutics (fka Cortexyme) Files 8-K — Oct 17, 2025 Risk: low
  On October 17, 2025, Quince Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 611 Gateway Bo
• Quince Therapeutics Enters Material Definitive Agreement — Sep 26, 2025 Risk: medium
  On September 25, 2025, Quince Therapeutics, Inc. entered into a material definitive agreement. This agreement also creates a direct financial obligation or an o
• Quince Therapeutics Files 8-K — Jul 16, 2025 Risk: low
  Quince Therapeutics, Inc. (formerly Cortexyme, Inc.) filed an 8-K on July 16, 2025, reporting on events including Regulation FD disclosures, other events, and f
• Quince Therapeutics Files 8-K with Material Agreement — Jun 13, 2025 Risk: medium
  On June 12, 2025, Quince Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• Quince Therapeutics Files 8-K on Security Holder Vote — Jun 5, 2025 Risk: low
  Quince Therapeutics, Inc. (formerly Cortexyme, Inc.) filed an 8-K on June 5, 2025, reporting on a matter submitted to a vote of its security holders on June 4,
• Quince Therapeutics Files 8-K: Other Events — Nov 14, 2024 Risk: medium
  On November 12, 2024, Quince Therapeutics, Inc. (formerly Cortexyme, Inc.) filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a signif
• Quince Therapeutics Faces Delisting Concerns — Jun 21, 2024 Risk: high
  Quince Therapeutics, Inc. filed an 8-K on June 21, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company
• Quince Therapeutics Files 8-K on Shareholder Vote — Jun 6, 2024 Risk: low
  Quince Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders on June 5, 2024. The company, formerly know
• Quince Therapeutics Reports Officer & Director Changes, Compensation — Feb 15, 2024 Risk: medium
  Quince Therapeutics, Inc. filed an 8-K on February 15, 2024, reporting events that occurred on February 13, 2024. The filing indicates changes in the company's
• Quince Therapeutics Files Routine 8-K on Jan 23 Event — Jan 29, 2024
  Quince Therapeutics, Inc. filed an 8-K on January 29, 2024, reporting an event that occurred on January 23, 2024. This filing is a standard current report, indi
• Quince Therapeutics Files Administrative 8-K on Dec 29, 2023 Event — Jan 3, 2024
  Quince Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an "Other Events" item that occurred on December 29, 2023. This filing primarily updates th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX